Administrative Core

CCII Cobre的目标是建立一个卓越的专题多学科研究中心 路易斯维尔大学，专注于提高我们对癌症免疫学的理解，并开发 新的免疫治疗方法。重要的是，随着最近免疫检查点的临床成功 抑制物和溶瘤病毒之间的相互作用引起了人们极大的兴趣和兴趣 宿主免疫系统和肿瘤细胞。我们的项目提出了基础免疫学研究，同时 翻译和人体样本研究有望最终导致全新的免疫疗法 方法，以及克服对现有药物的耐药性的战略。管理核心(AC) 将协调组成新中心的40多名个人的专业活动 癌症免疫学和免疫疗法(CCII)。AC将在行政、财政和科学方面提供 监督和规划初级调查人员、导师、项目、研究核心、试点计划和 咨询委员会。除管治职能外，咨询委员会还将提供关键的研究和指导 支持。这将包括授予项目赠款，指派导师，提供赠款撰写 导师计划、生物统计学和生物信息学支持、合规和监管监督、辅导 鼓励试点项目，鼓励多样性和包容性。内部顾问和外部顾问 由CCII专题领域五位顶尖科学家组成的委员会(EAC)将指导委员会。选管会 将就中心/项目进度提供科学指导和建设性反馈，并参与 CCII战略规划以及替代和试点项目的选择。整体CCII的两项PI 该计划将指导AC，并由两名具有丰富管理多个 组件赠款计划和来自另外两个有良好资格监督基本 生物统计学和生物信息学支持。他们的努力将补充一个指导计划，该计划的基础是 8名高级调查人员，他们是经验丰富的导师，在 主题领域。涵盖所有这些职能的行政核心的三个具体目标是 ：(1)建立CCII管理、规划和决策程序；(2)提供指导 加速CCII初级调查员职业生涯的方案；和(3)创建CCII试点赠款方案 这将刺激新的项目和合作。AC的创新功能建立在经验教训的基础上 建立其他多学科主题中心，并包括旨在 确保所有参与者的参与和全面的指导战略，以提供全面的 为我们的CCII初级调查人员提供指导。到5年资助计划结束时，我们预计4-6个CCII 初级调查员将获得R01奖金，其中许多毕业生仍将是关键 这个新的Cobre成员专注于癌症免疫学和免疫疗法。

The goal of the CCII COBRE is to establish a thematic multidisciplinary research center of excellence at the University of Louisville that focuses on improving our understanding of cancer immunology and developing novel immunotherapeutic approaches. Importantly, with the recent clinical successes of immune checkpoint inhibitors and oncolytic viruses, there is great interest and momentum in understanding the interaction between the host immune system and neoplastic cells. Our projects proposing basic immunology research coupled with translational and human specimen studies are expected to ultimately lead to entirely new immunotherapeutic approaches, as well as strategies for overcoming resistance to existing agents. The Administrative Core (AC) will coordinate the professional activities of the more than 40 individuals who will constitute the new Center for Cancer Immunology and Immunotherapy (CCII). The AC will provide administrative, fiscal, and scientific oversight and planning for junior investigators, mentors, projects, the research core, a pilot program, and advisory committees. In addition to governance functions, the AC will provide key research and mentoring support. This will include the awarding of project grants, assignment of mentors, provision of a grant writing mentorship program, biostatistics and bioinformatics support, compliance and regulatory oversight, mentoring of pilot projects, and encouragement of diversity and inclusion. Internal advisors and an External Advisory Committee (EAC) that consists of five leading scientists in the CCII thematic area will guide the AC. The EAC will provide scientific guidance and constructive feedback regarding center/project progress and be involved in CCII strategic planning and in the selection of replacement and pilot projects. The two PIs of the overall CCII program will direct the AC with key support from two co-Is who have extensive experience administering multi- component grant programs and from two additional co-Is who are well qualified to oversee the essential biostatistics and bioinformatics support. Their efforts will supplement a mentoring program that is anchored by eight senior investigators who are experienced mentors and have been highly productive and well funded in the thematic area. The three specific aims of this Administrative Core that encompass all of these functions are to: (1) Establish procedures for CCII administration, planning, and decision-making; (2) Provide a mentorship program to accelerate the careers of the CCII junior investigators; and (3) Create a CCII pilot grant program that will stimulate new projects and collaborations. Innovative features of the AC are built on lessons learned from establishing other multidisciplinary thematic centers and include a shared governance approach that aims to ensure engagement of all participants and a holistic mentoring strategy that provides comprehensive guidance for our CCII junior investigators. By the end of the 5-year funding program, we expect that 4-6 CCII junior investigators will have been awarded R01 grants and that many of these graduates will remain key members of this new COBRE focused on cancer immunology and immunotherapy.